aibioWhitehawk Therapeutics completes sale of Aadi Subsidiary to Kaken for $102.4 million
Tickers WHWK
The buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.
Key facts
- Company
- Whitehawk Therapeutics, Inc. (NASDAQ: WHWK)
- News type
- Mergers
- Primary source
- Whitehawk Therapeutics, Inc. 8-K (2025-03-26)
Whitehawk Therapeutics, Inc., which signed the deal as Aadi Bioscience, Inc., said it completed the sale of all of the outstanding shares of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC. on March 25, 2025.
At closing, the buyer paid Whitehawk a cash payment of $102.4 million, after purchase price adjustments under the agreement.
The stock purchase agreement was signed on December 19, 2024 among Aadi Bioscience, Inc., KAKEN INVESTMENTS INC., KAKEN PHARMACEUTICAL CO., LTD. and Aadi Subsidiary, Inc. The exhibit list in the filing names Aadi Bioscience, Inc. as the party to that agreement, the name under which Whitehawk signed it. The agreement was filed with a Current Report on Form 8-K on December 20, 2024.
Whitehawk said it intends to file pro forma financial information in an amendment to the report no later than four business days after the closing, according to the filing.